The study concluded that treatment with SGLT-2I in conjunction with GLP-1RA may help to reduce the incidence of AF/flutter ...

Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from ...

Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Key Takeaways Hims & Hers is now offering Zepbound and generic liraglutide for weight lossZepbound is priced at ...

Eli Lilly has launched legal attacks on two compounding pharmacies, accusing them of churning out unapproved Zepbound ...

While ChatGPT consistently produced responses that were factually correct in many cases, experts unanimously agreed that the ...

Singer Meghan Trainor has finally confirmed what fans have been speculating about for months—her dramatic weight loss wasn’t ...

Eli Lilly has sued two large compounding pharmacies, alleging they deceive patients and put them at risk with compounded ...

Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co.'s Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed ...